Current drug development for neurodegenerative diseases is limited by poor translation of preclinical animal models to clinical applications in humans. There is a pressing demand for breakthroughs, especially considering the expected rise in people affected by for instance Parkinson’s Disease (PD).
InnoSer uses advanced in-vitro brain models that implement human pluripotent stem cell-derived brain cell cultures, or organoids. These technologies can transform current in-vitro models by making use of healthy or patient-derived cells to study the phenotype, neuronal network formation and electrophysiological activity of these cells in a platform that allows for advanced read-out and a relevant, in-vivo-like microenvironment. By improving the predictive value of preclinical research we strive to reduce failing rates and costs for our customers.
Cancer is one of the leading causes of death in industrialized countries. Major breakthroughs in drug discovery for oncology have been hampered by the high costs and the high attrition rate. Classical human cancer models used are cancer cell lines (2D) and in vivo animal models. Although these oncology models have proven to be useful in the past their utility towards the clinic has vast room for improvement.
InnoSer has started exploring the field of tissue-derived organoids that are obtained during surgery or biopsy comprising of human tumor tissue that are termed Patient Derived Organoid (PDO). Long-term organoids (PDXO) exhibit dysplasia and invasiveness, phenotypically and genetically resembling the original patient-derived tumor. Recently InnoSer has teamed up with leading edge research groups from both academia and industrial partners which has led to a collaborative project to establish PDXO models from primary colon, esophagus, pancreas, stomach, liver, endometrium, prostate and breast tumors. InnoSer will validate the PDXO model using in vivo models to develop a fast and reliable screening model in the drug discovery and preclinical drug development chain.